TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04409600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Injection
Description: The participant will receive a saline injection to their painful lower leg compartment(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Injection
Description: The participant will receive a saline injection to their painful lower leg compartment(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Injection
Description: The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Injection
Description: The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
Study: NCT03003156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25 Hz magnetic seizure therapy
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 Hz magnetic seizure therapy
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study: NCT02736994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).
Description: Probiotic
Study: NCT02286856

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: diet intervention
Description: The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet intervention
Description: The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
Study: NCT05380232

Intervention type: BEHAVIORAL
Intervention: Leisure-time physical activity
Description: Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
Study: NCT03236233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786 - Single doses
Description: Safety and tolerability of single doses
Study: NCT00945542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massive transfusion protocol
Description: Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians.
Study: NCT02923063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise via videoconferencing
Description: Combined aerobic and resistance exercise session thrice weekly for 12 weeks
Study: NCT01353716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
Study: NCT03624777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outdoor Fall prevention brochure
Description: Participants in the wait list control group will initially receive written information only about preventing outdoor falls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroll Safe outdoor fall prevention program
Description: Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
Study: NCT02255487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IrriSept System
Description: The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention - Standard of Care (SoC) only
Description: Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
Study: NCT00297141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemotherapy oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy intravenous use
Study: NCT01520987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
Study: NCT02736994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corega Tabs Anti-bacteria®
Description: Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Water
Study: NCT00945542

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
Study: NCT00783965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazarotene
Description: Applied to the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazarotene
Description: Applied to the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Applied to the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Applied to the skin
Study: NCT01520987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily
Study: NCT04740424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS222
Description: Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
Study: NCT02077621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Powder for Injection, 500 mg PG2/500 ml normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mL normal saline
Study: NCT00564096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEEP TMS H1 coil
Description: A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep H1 coil TMS
Description: A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS.
Study: NCT00391534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified release formulation of oxcarbazepine (OXC MR)
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immediate release formulation of oxcarbazepine (OXC IR)
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Study: NCT00374166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR149415
Description: Oral administration (capsules of 50 and 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR149415
Description: Oral administration (capsules of 50 and 100 mg)
Study: NCT00374166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral administration (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration (capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration (capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Oral administration (capsules)
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy
Study: NCT00745940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT for TBI
Description: Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
Study: NCT04340297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)
Description: According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acid inhibitors
Description: In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
Study: NCT03236233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Single doses
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Single doses
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786 - Repeat doses
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Repeat doses
Description: Safety and tolerability of repeat doses
Study: NCT02817373

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound scan performed through a vaginal probe
Description: 5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
Study: NCT05843656

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-invasive brain stimulation
Description: based on sleep-physiology (slow-wave and spindles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: based on sleep-physiology (slow-wave and spindles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: based on sleep-physiology (slow-wave and spindles)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive brain stimulation
Description: based on sleep-physiology (slow-wave and spindles)
Study: NCT00684970

Intervention type: DRUG
Group type: OTHER
Intervention: Hamsa-1™ TL-118
Description: Once daily Hamsa-1™ TL-118
Study: NCT00477412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT04001504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Dose Quadrivalent Influenza Vaccine
Description: Double Dose QIV (30µg Hemagglutinin)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Quadrivalent Influenza Vaccine
Description: Standard Dose QIV (15µg Hemagglutinin)
Study: NCT02248454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Increasing insulin doses
Study: NCT04340297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acid inhibitors
Description: In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
Study: NCT02377206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADAS-Cog evaluation
Description: \[18F\]DPA-714 PET imaging
Study: NCT02014558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
Study: NCT02703233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Study: NCT01567735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
Study: NCT00722839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PADRE-CMV fusion peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PADRE-CMV fusion peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus-CMV fusion peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus-CMV fusion peptide vaccine
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agatolimod sodium
Description: Given subcutaneously
Study: NCT02014558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy